人福医药：HW231019片进入II期临床试验

Core Viewpoint - The announcement indicates that Yichang Renfu, a subsidiary of Renfu Pharmaceutical, has registered the Phase II clinical trial information for HW231019 tablets, which are intended for postoperative pain relief following abdominal surgery [1] Group 1: Clinical Trial Information - HW231019 tablets are being studied in a multicenter, randomized, double-blind, parallel, placebo-controlled trial to evaluate their efficacy and safety [1] - The trial is registered on the National Medical Products Administration's clinical trial registration and information disclosure platform [1] Group 2: Research and Development Investment - Yichang Renfu has invested approximately 20 million RMB in the research and development of this project [1]